#78 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need to recognize that older adults represent a rapidly growing cannabis user population, requiring updated screening protocols and knowledge of age-specific risks including drug interactions, fall risk, and cognitive effects. Geriatric patients on multiple medications may experience significant pharmacokinetic interactions with cannabis that alter efficacy of their existing treatments or increase adverse events. Understanding this demographic shift enables clinicians to provide informed counseling about edible-specific risks such as delayed onset and overdose in an age group potentially unfamiliar with cannabis products.
A University of Utah study documents that cannabis use among adults over 60 is increasing at a faster rate than any other age demographic, with edibles emerging as a preferred consumption method in this population. This trend has significant clinical implications as older adults often take multiple medications and have comorbidities that increase vulnerability to cannabis drug interactions, adverse effects, and falls, which represent a major safety concern in this age group. The shift toward edibles in particular warrants clinical attention since older patients may not appreciate delayed onset of effects or the difficulty in titrating dosing, potentially leading to overconsumption and unintended toxicity. Clinicians caring for older adults should routinely screen for cannabis use, particularly edible consumption, and counsel patients about drug interactions, dosing considerations, and fall risk given the physiologic changes in aging that affect cannabinoid metabolism and sensitivity. Patients and their families should understand that edible cannabis products carry specific risks in older populations due to variable and unpredictable absorption, longer duration of effects, and increased susceptibility to adverse events compared to younger users. Clinicians should proactively ask about cannabis edibles during medication reconciliation in older adult patients to mitigate preventable harms.
“What we’re seeing in my practice is that older adults are experimenting with edibles because they offer precise dosing and avoid the respiratory risks of smoking, but the critical issue is that this population is often on multiple medications with serious drug interactions we’re only beginning to understand, and without proper clinical guidance many of these patients are dosing themselves in the dark.”
🧠 While cannabis use among older adults represents a significant shift in consumption patterns that clinicians should recognize, the rapid uptake of edibles in this population warrants particular caution. Older adults often have altered pharmacokinetics due to age-related changes in metabolism and body composition, potentially leading to higher blood concentrations and prolonged effects compared to younger users; edibles present additional challenges because their delayed onset frequently leads users to consume additional product before experiencing effects, increasing overdose risk in a population already vulnerable to falls and cognitive impairment. The heterogeneity of cannabis products, variable labeling accuracy, and frequent polypharmacy in older adults compound the difficulty in predicting individual responses and drug interactions. Clinicians should routinely ask patients over 60 about cannabis use during medication reviews and substance use screening, providing clear counseling about edible potency and the risks of unintentional overconsumption, while remaining attuned
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
